New Delhi, Nov 17 (PTI) Alembic Pharmaceuticals on Wednesday said its joint venture Aleor Dermaceuticals Ltd (Aleor) has received approval from the US health regulator to market Mupirocin cream.

The approved abbreviated new drug application (ANDA) for Mupirocin cream is therapeutically equivalent to the reference listed drug product (RLD), Bactroban cream (2 per cent) of SmithKline Beecham (Cork) Ltd, Ireland, the company said.

Also Read | WB Police Excise Constable PET,PMT Admit Card 2019 Released, Candidates Can Download Their Admit Cards Online wbpolice.gov.in.

Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S aureus and S pyogenes.

Aleor has been granted a competitive generic therapies (CGT) designation for this ANDA and it is eligible for 180 days of exclusivity as it is the first approved applicant, Alembic Pharmaceuticals said in a statement.

Also Read | WhatsApp Desktop App Now Available on Windows App Store, Here's How To Download It.

According to IQVIA, Mupirocin cream USP, 2 per cent has an estimated market size of USD 28 million for the twelve months ended June 2021.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)